Pulmonary Arterial Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Pulmonary arterial hypertension Pipeline Drugs Market Report Overview

Pulmonary arterial hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Key Targets in the Pulmonary Arterial Hypertension Pipeline Market

The key targets in the pulmonary arterial hypertension pipeline market are Prostacyclin Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Endothelin 1 Receptor, Platelet Derived Growth Factor Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Soluble Guanylate Cyclase. Prostacyclin Receptor has the highest pipeline products in the pulmonary arterial hypertension pipeline market.

Pulmonary Arterial Hypertension Pipeline Market, by Targets

Pulmonary Arterial Hypertension Pipeline Market, by Targets

For more target insights, download a free report sample

Key Types of MoA in the Pulmonary Arterial Hypertension Pipeline Market

The key types of MoA in the pulmonary arterial hypertension pipeline market are Prostacyclin Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Endothelin 1 Receptor Antagonist, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Platelet Derived Growth Factor Receptor Inhibitor, Soluble Guanylate Cyclase Activator, and 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor. Prostacyclin Receptor Agonist has the highest pipeline products.

Pulmonary Arterial Hypertension Pipeline Market, by MoA

Pulmonary Arterial Hypertension Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key Types of RoA in the Pulmonary Arterial Hypertension Pipeline Market

The key types of RoA in the pulmonary arterial hypertension pipeline market are oral, inhalational, intravenous, subcutaneous, topical, intramuscular, and parenteral. Oral has the highest share in the pulmonary arterial hypertension pipeline market.

Pulmonary Arterial Hypertension Pipeline Market, by RoA

Pulmonary Arterial Hypertension Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Pulmonary Arterial Hypertension Pipeline Market

The key molecule types in the pulmonary arterial hypertension pipeline market are small molecule, fusion protein, monoclonal antibody, oligonucleotide, recombinant protein, gene-modified cell therapy, synthetic peptide, and aptamer. Small molecule has the highest share in the pulmonary arterial hypertension pipeline market.

Key Molecule Types in the Pulmonary Arterial Hypertension Pipeline Market

For more molecule type insights, download a free report sample

Key Companies in the Pulmonary Arterial Hypertension Pipeline Market

The key companies in the Pulmonary Arterial Hypertension pipeline market are United Therapeutics Corp, Chiesi Farmaceutici SpA, Gmax Biopharm LLC, VasThera Co Ltd, Altavant Sciences Inc, Alterras Therapeutics GmbH, and Antlia Bioscience Inc. United Therapeutics Corp has the highest share in the Pulmonary Arterial Hypertension pipeline market.

Key Companies in the Pulmonary Arterial Hypertension Pipeline Market

To know more about companies, download a free report sample

Market report overview

Key Targets Prostacyclin Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Endothelin 1 Receptor, Platelet Derived Growth Factor Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Soluble Guanylate Cyclase
Key Types of MoA Prostacyclin Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Endothelin 1 Receptor Antagonist, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Platelet Derived Growth Factor Receptor Inhibitor, Soluble Guanylate Cyclase Activator, and 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor
Key Types of RoA Oral, Inhalational, Intravenous, Subcutaneous, Topical, Intramuscular, and Parenteral
Key Molecule Types Small Molecule, Fusion Protein, Monoclonal Antibody, Oligonucleotide, Recombinant Protein, Gene-Modified Cell Therapy, Synthetic Peptide, and Aptamer
Key Companies United Therapeutics Corp, Chiesi Farmaceutici SpA, Gmax Biopharm LLC, VasThera Co Ltd, Altavant Sciences Inc, Alterras Therapeutics GmbH, and Antlia Bioscience Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Aadi Bioscience Inc
Abivax SA
Acceleron Pharma Inc
Advent Therapeutics Inc
Aeon Respire Inc
Aerami Therapeutics Inc
Aerogen Pharma Corp
Aerovate Therapeutics Inc
AI Therapeutics Inc
Algorithm Sciences Inc
Altavant Sciences Inc
Alterras Therapeutics GmbH
Alveolus Bio Inc
Antlia Bioscience Inc
Apaxen
APEIRON Biologics AG
Apollo Therapeutics LLC
APT Therapeutics Inc
Aqualung Therapeutics Corp
Arovella Therapeutics Ltd
AstraZeneca Plc
ATXA Therapeutics Ltd
Bayer AG
Bial - Portela & Ca SA
Biogen Inc
Biozeus Pharmaceutical SA
Boehringer Ingelheim International GmbH
C4X Discovery Holdings Plc
Camurus AB
Capricor Therapeutics Inc
Cardiorentis AG
Celon Pharma SA
Celsion Corp
Celtaxsys Inc
Centessa Pharmaceuticals Plc
Cereno Scientific AB
Chengdu Dikang Pharmaceuticals Co Ltd
Chiesi Farmaceutici SpA
Claritas Pharmaceuticals Inc
Corsair Pharma Inc
Denovo Biopharma LLC
Eli Lilly and Co
Excubio Pharmaceuticals Inc
Galectin Therapeutics Inc
GenThera Inc
GEXVal Inc
Gilead Sciences Inc
Gmax Biopharm LLC
Gossamer Bio Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
Insmed Inc
Interprotein Corp
INVENT Pharmaceuticals Inc
Johnson & Johnson
Keros Therapeutics Inc
Les Laboratoires Servier SAS
Liquidia Technologies Inc
LTT Bio-Pharma Co Ltd
Martin Pharmaceuticals Inc
Merck & Co Inc
Morphic Therapeutic Inc
Nadian Bio Ltd
Nippon Shinyaku Co Ltd
Nissan Chemical Corp
Northern Therapeutics Inc
Novartis AG
Pharmosa Biopharm Inc
Proteo Inc
PulmoSIM Therapeutics
Q BioMed Inc
Radikal Therapeutics Inc
Recursion Pharmaceuticals Inc
Respira Therapeutics Inc
Resverlogix Corp
Reviva Pharmaceuticals Inc
Ribomic Inc
Shijiazhuang Sagacity New Drug Development Co Ltd
ShouTi Inc
SteadyMed Therapeutics Inc
Sulfateq BV
Systimmune Inc
Tenax Therapeutics Inc
Topadur Pharma AG
Translate Bio Inc
Triastek Inc
Tritech Biopharmaceuticals Co Ltd
United Therapeutics Corp
Vascular BioSciences
Vasculonics LLC
VasThera Co Ltd
Vicore Pharma AB
Vivus LLC
Voronoi Group
Zymedi

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pulmonary Arterial Hypertension – Overview

Pulmonary Arterial Hypertension – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pulmonary Arterial Hypertension – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pulmonary Arterial Hypertension – Companies Involved in Therapeutics Development

Pulmonary Arterial Hypertension – Drug Profiles

Pulmonary Arterial Hypertension – Dormant Projects

Pulmonary Arterial Hypertension – Discontinued Products

Pulmonary Arterial Hypertension – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pulmonary Arterial Hypertension – Dormant Projects, 2022

Pulmonary Arterial Hypertension – Dormant Projects, 2022 (Contd..1)

Pulmonary Arterial Hypertension – Dormant Projects, 2022 (Contd..2)

Pulmonary Arterial Hypertension – Dormant Projects, 2022 (Contd..3)

Pulmonary Arterial Hypertension – Dormant Projects, 2022 (Contd..4)

Pulmonary Arterial Hypertension – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Pulmonary Arterial Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pulmonary Arterial Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Pulmonary Arterial Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.